TABLE 1.
Descriptive characteristics of 50 patients with ankylosing spondylitis, overall and stratified by sex
| Total, n = 50 | Men, n = 33 (66.0%) | Women, n = 17 (34.0%) | P value | |
|---|---|---|---|---|
| Age, years | 54.5 (45.5–60.0) | 53.0 (45.5–60.0) | 56.0 (44.5–60.5) | .6 |
| BMI, kg/m2 | 26.2 (23.4–31.1) | 27.0 (23.5–32.9) | 25.0 (23.1–28.0) | .1 |
| Ever smoker | 18 (36) | 11 (33.3) | 7 (41.2) | .6 |
| Symptom duration, years | 31.0 (21.0–39.0) | 32.0 (21.5–39.5) | 30.0 (20.5–38.0) | .7 |
| HLA‐B27 positive | 50 (100) | |||
| ESR, mm/h | 8.0 (3.8–15.2) | 6.0 (4.9–14.5) | 10.0 (3.0–18.5) | .5 |
| hsCRP, mg/L | 2.1 (0.8–5.2) | 1.8 (0.8–6.0) | 2.3 (0.7–3.8) | .8 |
| History of anterior uveitis | 26 (52.0) | 17 (51.5) | 9 (52.9) | .9 |
| History of peripheral arthritis | 30 (60.0) | 22 (66.7) | 8 (47.0) | .2 |
| ASDAS‐CRP, score | 1.8 (1.2–2.2) | 1.8 (1.3–2.3) | 1.8 (1.2–2.2) | .7 |
| BASDAI, score | 3.4 (2.2–5.5) | 3.1 (2.0–5.5) | 4.0 (3.2–5.4) | .2 |
| BASFI, score | 2.2 (0.9–3.9) | 2.1 (0.8–4.0) | 2.5 (1.0–4.0) | .7 |
| BASMI, score | 3.2 (2.4–5.2) | 4.0 (2.5–5.5) | 3.0 (2.4–4.1) | .2 |
| NSAID, regular use | 30 (60.0) | 19 (57.6) | 11 (64.7) | .6 |
| csDMARD | 7 (14.0) | 7 (21.1) | 0 (0) | .08 |
| bDMARD | 12 (24.0) | 10 (30.3) | 2 (11.8) | .2 |
| csDMARD and/or bDMARD | 14 (28.0) | 12 (36.4) | 2 (11.8) | .1 |
| mSASSS, score | 4 (0–31.0) | 18.0 (2.5–42.0) | 1.0 (0.0–5.5) | .006* |
| Syndesmophyte presence | 23 (46.0) | 19 (57.6) | 4 (23.5) | .02* |
Note: Values are presented as median with interquartile range (IQR) or number of patients and percent (%).
Abbreviations: ASDAS, Ankylosing Spondylitis Disease Activity Score; b, biologic (i.e. anti‐TNF antibodies); BASDAI, Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; csDMARD, conventional synthetic disease‐modifying anti‐rheumatic drug; ESR, erythrocyte sedimentation rate; HLA‐B27, human leucocyte antigen B27; hsCRP, high‐sensitivity C‐reactive protein; mSASSS, Modified Stoke Ankylosing Spondylitis Score; NSAID, non‐steroidal anti‐inflammatory drug. *P ≤ .05.